{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T11:17:04Z","timestamp":1781608624384,"version":"3.54.5"},"reference-count":30,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2021,7,2]],"date-time":"2021-07-02T00:00:00Z","timestamp":1625184000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:p><jats:bold>Background:<\/jats:bold> Cardiovascular events are one of the most serious complications that increase the risk of mortality and morbidity in pre-dialysis and on-dialysis chronic kidney disease (CKD) patients. Activation of the renin\u2013angiotensin\u2013aldosterone system (RAAS) is considered to contribute to the development of cardiovascular events in these populations. Therefore, several kinds of RAAS blockers have been frequently prescribed to prevent cardiovascular events in patients with CKD; however, their effectiveness remains controversial. This systematic review focuses on whether RAAS blockers prevent cardiovascular events in patients with CKD.<\/jats:p><jats:p><jats:bold>Method:<\/jats:bold> PubMed were searched to retrieve reference lists of eligible trials and related reviews. Randomized prospective controlled trials that investigated the effects on cardiovascular events in CKD patients that were published in English from 2010 to 2020 were included.<\/jats:p><jats:p><jats:bold>Results:<\/jats:bold> Among 167 identified studies, 11 eligible studies (<jats:italic>n<\/jats:italic> = 8,322 subjects) were included in the meta-analysis. The meta-analysis showed that RAAS blockers significantly reduced cardiovascular events in on-dialysis patients with CKD [three studies; odds ratio (OR), 0.52; 95% confidence interval (CI), 0.36 to 0.74; <jats:italic>p<\/jats:italic> = 0.0003], but there was no significant difference in pre-dialysis patients with CKD because of the heterogeneity in each study (eight studies). We also investigated the effects of each kind of RAAS blocker on cardiovascular events in CKD patients. Among the RAAS blockers, mineralocorticoid receptor antagonists significantly decreased cardiovascular events in pre-dialysis or on-dialysis patients with CKD (four studies; OR, 0.60; 95%CI, 0.50 to 0.73, <jats:italic>p<\/jats:italic> &amp;lt; 0.0001). However, angiotensin receptor blockers did not show significant effects (four studies; OR, 0.65; 95%CI, 0.42 to 1.01; <jats:italic>p<\/jats:italic> = 0.0529). The effects of angiotensin converting enzyme inhibitors and direct renin inhibitors on cardiovascular events in patients with CKD could not be analyzed because there were too few studies.<\/jats:p><jats:p><jats:bold>Conclusion:<\/jats:bold> Mineralocorticoid receptor antagonists may decrease cardiovascular events in pre-dialysis or on-dialysis patients with CKD.<\/jats:p>","DOI":"10.3389\/fphar.2021.662544","type":"journal-article","created":{"date-parts":[[2021,7,2]],"date-time":"2021-07-02T07:48:33Z","timestamp":1625212113000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":15,"title":["Systematic Review and Meta-Analysis of Renin\u2013Angiotensin\u2013Aldosterone System Blocker Effects on the Development of Cardiovascular Disease in Patients With Chronic Kidney Disease"],"prefix":"10.3389","volume":"12","author":[{"given":"Katsunori","family":"Yanai","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenichi","family":"Ishibashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshiyuki","family":"Morishita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2021,7,2]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"e0224858","DOI":"10.1371\/journal.pone.0224858","article-title":"Genetic Susceptibility to Angiotensin-Converting Enzyme-Inhibitor Induced Angioedema: A Systematic Review and Evaluation of Methodological Approaches","volume":"14","author":"Ali","year":"2019","journal-title":"PLoS One"},{"key":"B2","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1016\/j.ijcard.2011.12.056","article-title":"Effects of Enalapril in Systolic Heart Failure Patients with and without Chronic Kidney Disease: Insights from the SOLVD Treatment Trial","volume":"167","author":"Bowling","year":"2013","journal-title":"Int. J. Cardiol."},{"key":"B3","doi-asserted-by":"publisher","first-page":"1176","DOI":"10.1161\/CIRCRESAHA.111.245092","article-title":"Treatment of Chronic Heart Failure with \u03b2-Adrenergic Receptor Antagonists","volume":"109","author":"Bristow","year":"2011","journal-title":"Circ. Res."},{"key":"B4","doi-asserted-by":"publisher","first-page":"1701","DOI":"10.1016\/j.jacc.2010.03.105","article-title":"Effects of Telmisartan Added to Angiotensin-Converting Enzyme Inhibitors on Mortality and Morbidity in Hemodialysis Patients with Chronic Heart Failure","volume":"56","author":"Cice","year":"2010","journal-title":"J. Am. Coll. Cardiol."},{"key":"B5","doi-asserted-by":"publisher","first-page":"1585","DOI":"10.1016\/j.jacc.2013.04.086","article-title":"Safety and Efficacy of Eplerenone in Patients at High Risk for Hyperkalemia And\/or Worsening Renal Function","volume":"62","author":"Eschalier","year":"2013","journal-title":"J. Am. Coll. Cardiol."},{"key":"B6","doi-asserted-by":"publisher","first-page":"F181","DOI":"10.1152\/ajprenal.2001.280.2.F181","article-title":"Multiple Aspects of Mineralocorticoid Selectivity","volume":"280","author":"Farman","year":"2001","journal-title":"Am. J. Physiology-Renal Physiol."},{"key":"B7","doi-asserted-by":"publisher","first-page":"1892","DOI":"10.1056\/NEJMoa1303154","article-title":"Combined Angiotensin Inhibition for the Treatment of Diabetic Nephropathy","volume":"369","author":"Fried","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"B8","doi-asserted-by":"publisher","first-page":"936","DOI":"10.1111\/epi.12132","article-title":"A Systematic Review and Meta-Analysis of the Role ofABCC2variants on Drug Response in Patients with Epilepsy","volume":"54","author":"Grover","year":"2013","journal-title":"Epilepsia"},{"key":"B9","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1186\/s41232-017-0046-5","article-title":"Pathophysiology and Therapeutic Potential of Cardiac Fibrosis","volume":"37","author":"Hara","year":"2017","journal-title":"Inflamm. Regener"},{"key":"B10","doi-asserted-by":"publisher","first-page":"2978","DOI":"10.1007\/s00125-011-2325-z","article-title":"Effects of Olmesartan on Renal and Cardiovascular Outcomes in Type 2 Diabetes with Overt Nephropathy: a Multicentre, Randomised, Placebo-Controlled Study","volume":"54","author":"Imai","year":"2011","journal-title":"Diabetologia"},{"key":"B11","doi-asserted-by":"publisher","first-page":"e13309","DOI":"10.14814\/phy2.13309","article-title":"Sodium Balance, Circadian BP Rhythm, Heart Rate Variability, and Intrarenal Renin-Angiotensin-Aldosterone and Dopaminergic Systems in Acute Phase of ARB Therapy","volume":"5","author":"Isobe-Sasaki","year":"2017","journal-title":"Physiol. Rep."},{"key":"B12","doi-asserted-by":"publisher","first-page":"497","DOI":"10.3109\/10641963.2013.863323","article-title":"Effects of Aliskiren on Blood Pressure and Humoral Factors in Hypertensive Hemodialysis Patients Previously on Angiotensin II Receptor Antagonists","volume":"36","author":"Ito","year":"2014","journal-title":"Clin. Exp. Hypertens."},{"key":"B13","doi-asserted-by":"publisher","first-page":"3150","DOI":"10.1038\/s41598-018-20874-4","article-title":"Cardiovascular and Renal Protective Role of Angiotensin Blockade in Hypertension with Advanced CKD: a Subgroup Analysis of ATTEMPT-CVD Randomized Trial","volume":"8","author":"Kim-Mitsuyama","year":"2018","journal-title":"Sci. Rep."},{"key":"B14","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1111\/jch.12628","article-title":"Long-Term Effects of Low-Dose Spironolactone on Chronic Dialysis Patients: A Randomized Placebo-Controlled Study","volume":"18","author":"Lin","year":"2016","journal-title":"J. Clin. Hypertens."},{"key":"B15","first-page":"2918","article-title":"Cardiovascular Disease and its Relationship with Chronic Kidney Disease","volume":"18","author":"Liu","year":"2014","journal-title":"Eur. Rev. Med. Pharmacol. Sci."},{"key":"B16","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1038\/hr.2010.238","article-title":"Effects of Aliskiren on Blood Pressure and the Predictive Biomarkers for Cardiovascular Disease in Hemodialysis-dependent Chronic Kidney Disease Patients with Hypertension","volume":"34","author":"Morishita","year":"2011","journal-title":"Hypertens. Res."},{"key":"B17","doi-asserted-by":"publisher","first-page":"668","DOI":"10.5812\/numonthly.3679","article-title":"Direct Renin Inhibitor: Aliskiren in Chronic Kidney Disease","volume":"5","author":"Morishita","year":"2013","journal-title":"Nephro Urol. Mon"},{"key":"B18","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1097\/HJH.0b013e32834dde5f","article-title":"Telmisartan Ameliorates Lipopolysaccharide-Induced Innate Immune Response through Peroxisome Proliferator-Activated Receptor-\u03b3 Activation in Human Monocytes","volume":"30","author":"Pang","year":"2012","journal-title":"J. Hypertens."},{"key":"B19","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1016\/j.trsl.2019.03.001","article-title":"Cardiac Fibrosis: Potential Therapeutic Targets","volume":"209","author":"Park","year":"2019","journal-title":"Translational Res."},{"key":"B20","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1007\/s40265-019-1064-1","article-title":"Management of Hypertension in Chronic Kidney Disease","volume":"79","author":"Pugh","year":"2019","journal-title":"Drugs"},{"key":"B21","doi-asserted-by":"publisher","first-page":"442","DOI":"10.3109\/0886022X.2011.649672","article-title":"Efficacy of Aliskiren in Japanese Chronic Kidney Disease Patients with Hypertension","volume":"34","author":"Sakai","year":"2012","journal-title":"Ren. Fail."},{"key":"B22","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1161\/01.hyp.0000044937.95080.e9","article-title":"Effectiveness of Aldosterone Blockade in Patients with Diabetic Nephropathy","volume":"41","author":"Sato","year":"2003","journal-title":"Hypertension"},{"key":"B23","doi-asserted-by":"publisher","first-page":"g7647","DOI":"10.1136\/bmj.g7647","article-title":"Preferred Reporting Items for Systematic Review and Meta-Analysis Protocols (PRISMA-P) 2015: Elaboration and Explanation","volume":"349","author":"Shamseer","year":"2015","journal-title":"BMJ"},{"key":"B24","doi-asserted-by":"publisher","first-page":"1098","DOI":"10.1161\/CIRCULATIONAHA.110.964171","article-title":"Cardiovascular and Renal Outcomes with Telmisartan, Ramipril, or Both in People at High Renal Risk","volume":"123","author":"Tobe","year":"2011","journal-title":"Circulation"},{"key":"B25","doi-asserted-by":"publisher","first-page":"205435811985411","DOI":"10.1177\/2054358119854113","article-title":"Characteristics of Adults with Type 2 Diabetes Mellitus by Category of Chronic Kidney Disease and Presence of Cardiovascular Disease in Alberta Canada: A Cross-Sectional Study","volume":"6","author":"Tonelli","year":"2019","journal-title":"Can. J. Kidney Health Dis."},{"key":"B26","doi-asserted-by":"publisher","first-page":"2267","DOI":"10.1056\/NEJMoa1402686","article-title":"Angiotensin Blockade in Late Autosomal Dominant Polycystic Kidney Disease","volume":"371","author":"Torres","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"B27","doi-asserted-by":"publisher","first-page":"1268","DOI":"10.1177\/2047487318780035","article-title":"Efficacy of Renin-Angiotensin System Inhibitors for Patients with Heart Failure with Preserved Ejection Fraction and Mild to Moderate Chronic Kidney Disease","volume":"25","author":"Tsujimoto","year":"2018","journal-title":"Eur. J. Prev. Cardiolog"},{"key":"B28","doi-asserted-by":"publisher","first-page":"1602","DOI":"10.2215\/CJN.12371214","article-title":"The Safety of Eplerenone in Hemodialysis Patients: A Noninferiority Randomized Controlled Trial","volume":"10","author":"Walsh","year":"2015","journal-title":"Cjasn"},{"key":"B29","doi-asserted-by":"publisher","first-page":"728","DOI":"10.1053\/j.ajkd.2015.10.011","article-title":"Renin-Angiotensin System Inhibitors and Kidney and Cardiovascular Outcomes in Patients with CKD: A Bayesian Network Meta-Analysis of Randomized Clinical Trials","volume":"67","author":"Xie","year":"2016","journal-title":"Am. J. Kidney Dis."},{"key":"B30","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1007\/s11906-017-0771-9","article-title":"Effects of RAAS Inhibitors in Patients with Kidney Disease","volume":"19","author":"Zhang","year":"2017","journal-title":"Curr. Hypertens. Rep."}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2021.662544\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,7,2]],"date-time":"2021-07-02T07:48:35Z","timestamp":1625212115000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2021.662544\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7,2]]},"references-count":30,"alternative-id":["10.3389\/fphar.2021.662544"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2021.662544","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,7,2]]},"article-number":"662544"}}